Evidence map›Paper›PMID 25197377›Full record

ArticleInternational journal of clinical and experimental pathology2014

Clinical characteristics of 26 patients with primary extranodal Hodgkin lymphoma.

Jing Ma, Yafei Wang, Haifeng Zhao, Su Liu, Qian Li, Li Lin, Yuanfang Yue, Xiaofang Wang, Zhigang Zhao, Yong Yu and 1 more

Abstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jing MaDepartment of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
Yafei WangDepartment of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
Haifeng ZhaoDepartment of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
Su LiuDepartment of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
Qian LiDepartment of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
Li LinDepartment of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
Yuanfang YueDepartment of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
Xiaofang WangDepartment of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
Zhigang ZhaoDepartment of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
Yong YuDepartment of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
Yizhuo ZhangDepartment of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMost Hodgkin lymphoma (HL) patients present with disease in nodal regions. However, in a small subset, disease develops extranodal sites primarily, such as lung and liver. This study aims to identify the characteristics and outcomes of patients with primary extranodal HL.

methodsA retrospective analysis of patients with HL from 1998 to 2012 was enrolled. We selected 26 HL patients with primary extranodal involvement from 251 previously untreated HL patients. All data analyses were performed with SPSS software version 17.0 and GraphPad Prism 5.

resultsWe identified 26 patients with primary extranodal HL. Results in the series of young patients, male predominated. Pathologically, the major pathologic types were nodular sclerosis classical HL (NSCHL, 46.2%) and mixed cellularity classical HL (MCCHL, 38.5%). Thirteen patients had early stage (I or II stage). The most commonly primarily extranodal sites were the lung and the stomach and intestine, followed by the liver and bones. Fifteen of 26 received chemotherapy alone and 11 received combination therapy. Finally, primary extranodal HLs in our study have a favorable survival. Furthermore, there was no significant association between the international prognostic score (IPS) and survival in patients with extranodal HL.

conclusionOur retrospective data in part reflect clinical characteristics of primary extranodal HL in China, and form the basis for further concerning researches.

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsChemoradiotherapyDisease-Free SurvivalFemaleGastrointestinal NeoplasmsHodgkin DiseaseHumansKaplan-Meier EstimateLung NeoplasmsMaleProportional Hazards ModelsRetrospective Studies18F-FDGPET-CTextranodalHodgkin’s lymphomainternational prognostic scoreprognosissurvival

Identifiers

PMID25197377
PMCPMC4152067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.